fig2

Isocucurbitacin B inhibits glioma growth through PI3K/AKT pathways and increases glioma sensitivity to TMZ by inhibiting hsa-mir-1286a

Figure 2. (A) mRNA expression levels in common tumor tissues; (B) The mRNA expression levels in common tumor tissues (*P < 0.05 vs. control group); (C) Mutation, deep deletion, and amplification of AKT1 in gliomas. Green, blue, and red indicate mutations, deep deletions, and amplifications, respectively. AKT1 methylation is negatively correlated with the expression of AKT1 in glioma tissues (****P < 0.0001 vs. control group). The AKT1 gene has a low methylation level in gliomas. (****P < 0.0001 vs. control group); (D) Mutations, deep deletions, and MAPK1 amplification in glioma cells. Green indicates mutations. Different types of MAPK1 mutations. Different types of MAPK1 mutation in glioma at different levels. AKT1: AKT serine/threonine kinase 1; MAPK1: mitogen-activated protein kinase 1.

Cancer Drug Resistance
ISSN 2578-532X (Online)

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/